The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen has announced it will release its third quarter 2026 financial results on Wednesday, November 4, at 8:30 a.m. Eastern Time.
The company will host a conference call and webcast to provide a business update and discuss its latest financial performance. Investors can access further details through the provided webcast link in the announcement.
View post on X Loading...
Ocugen recently signed an OCU400 licensing agreement with Roots Pharmaceutical for the MENA region, valued at up to $259 million in milestones and royalties, according to a previous announcement. The company has also advanced its OCU410 gene therapy for geographic atrophy into a Phase 3 clinical trial, as reported earlier. These developments come as Ocugen prepares to share its third quarter 2026 financial results.